A few years ago, almost nobody outside an endocrinology clinic had heard of GLP-1. Now the drugs that act on it — Ozempic, Wegovy, Mounjaro, Zepbound — are household names, and they've reshaped how medicine thinks about obesity and type 2 diabetes. If you've been prescribed one, or you're reading about them because a family member has, the marketing rarely explains the part that actually matters: what is this drug doing inside your body, and why does it work?
This explainer walks through the biology without the jargon. We're not going to tell you whether one of these drugs is right for you — that's a conversation for you and your doctor — but you'll come away understanding the mechanism well enough to ask better questions.
What GLP-1 actually is
GLP-1 stands for glucagon-like peptide-1. It's a hormone your own body makes — specifically, it's released by cells in your gut within minutes of you starting to eat. It belongs to a family called incretins, whose job is essentially to tell the rest of the body, "food is arriving, get ready."
Natural GLP-1 does several things at once. It nudges the pancreas to release insulin, but only when blood sugar is actually rising — which is part of why these drugs rarely cause dangerously low blood sugar on their own. It tells the liver to stop dumping stored glucose into the bloodstream. It slows down how quickly your stomach empties, so food lingers and you feel full longer. And it acts on the appetite centers of the brain, turning down hunger signals.
The catch is that natural GLP-1 is destroyed within a couple of minutes by an enzyme called DPP-4. So even though your body makes it, the effect is fleeting. The breakthrough behind these drugs was building a molecule that does the same job but resists that enzyme — so instead of lasting minutes, it lasts days.
What "agonist" means here
An agonist is simply a molecule that switches on a receptor. Your cells are covered in receptors — think of them as locks — and an agonist is a key that fits one and turns it on. A GLP-1 receptor agonist is a drug designed to fit the GLP-1 lock and activate it, imitating the natural hormone but sticking around far longer.
That's why a drug like semaglutide (the molecule inside Ozempic and Wegovy) can be injected just once a week. It clings to a protein in your blood that shields it from being broken down, so a single dose keeps the receptor gently switched on for days. The result is a steady, round-the-clock version of a signal your body normally only sends in short bursts.
Why it leads to weight loss
The weight-loss effect, which is what most people have heard about, comes mostly from two of those mechanisms working together. The slowed stomach emptying means you feel physically full sooner and for longer. The brain effect reduces the background drive to eat — many people describe it as the "food noise" going quiet. You're not white-knuckling through hunger; the hunger signal itself is dialed down.
It's worth being honest about what this does and doesn't mean. The drugs don't melt fat directly. They change appetite and eating behavior, and the weight loss follows from eating less. That also explains why weight tends to return when people stop — remove the drug, the hunger signal comes back to its old level.
From single to dual and triple agonists
The first generation of these drugs targeted only the GLP-1 receptor. The newer ones go further. Tirzepatide — the molecule in Mounjaro and Zepbound — activates GLP-1 and a second incretin receptor called GIP. Hitting two targets at once turned out to produce stronger results for many people, which is why tirzepatide generally shows larger average weight loss in head-to-head data than the single-target drugs.
The frontier now is triple agonists — molecules that add a third target, glucagon, into the mix. Retatrutide is the most talked-about example, still working its way through clinical testing. The logic is that each hormone receptor controls a slightly different lever — appetite, energy use, fat metabolism — and pulling several at once may do more than pulling one. Whether the added benefit is worth any added side effects is exactly the kind of question trials are built to answer.
The side effects, and why they happen
Most of the common side effects make sense once you understand the mechanism. Because the drug slows the stomach and acts on the gut, nausea, constipation, and occasional vomiting are the usual complaints — especially in the first weeks, and especially when the dose is increased. That's why doctors start low and step the dose up slowly: it gives the gut time to adjust.
There are rarer concerns that get studied more carefully, including pancreatitis and a thyroid tumor signal seen in rodents (the human relevance of which is still debated, but it's why these drugs carry a warning for people with certain inherited thyroid cancer syndromes). More recently, attention has turned to what happens to muscle: rapid weight loss of any kind takes some muscle along with fat, and researchers are actively studying how to preserve lean mass during treatment.
What's still being figured out
Here's the part the headlines often skip: a lot about this drug class is still genuinely unknown, and that's where current research is focused. The big open questions include how to maintain weight loss after stopping, whether these drugs protect the heart and kidneys in people who don't have diabetes, what very long-term use does, and whether the same mechanism helps conditions that seem unrelated to weight — sleep apnea, fatty liver disease, even addiction and Alzheimer's are all under investigation.
This is why you'll see so many GLP-1 studies recruiting at any given time. The molecule opened a door, and the field is now walking through every room behind it. If you want to see which of those questions are being actively tested in people, our guide to GLP-1 clinical trials tracks the active studies, and our obesity trials overview covers the broader landscape.
The short version
GLP-1 agonists copy a natural gut hormone that tells your body it's been fed. By making that signal last for days instead of minutes, they lower blood sugar and quiet appetite — and the newer versions hit two or three hormone targets at once for a stronger effect. They're not magic and they're not without trade-offs, but understanding the mechanism is the first step to having a clear-eyed conversation about whether they belong in your treatment plan.